Second-Generation Antihistamine OTC Labeling Could Resemble Monograph
This article was originally published in The Tan Sheet
Executive Summary
OTC labeling for second-generation antihistamines - if the drugs were to switch - may not differ greatly from warnings on existing nonprescription allergic rhinitis symptom relief drugs.
You may also be interested in...
Zyrtec OTC Switch: Pfizer Says Rx Status Necessary For “Best Use” Of Drug
A forced OTC switch of Zyrtec would deprive consumers of the "health information component" doctors provide, which is needed for optimal care, Pfizer CEO Henry McKinnell said during the firm's April 24 annual meeting in Ann Arbor, Mich
Allegra Marketing Strategy “Drives On” In Response To Claritin Switch
Aventis will not change its marketing strategy for Allegra following the Rx-to-OTC switch of Schering-Plough's Claritin
Allegra Asthma Claim Would Be Key Defense Vs. Forced OTC Switch – Aventis
Aventis' Allegra experimental asthma indication would be the best defense against a forced OTC switch of the antihistamine, Chief Operating Officer Richard Markham told analysts during Aventis' R&D day in London June 18